erlotinib hydrochloride has been researched along with Coronavirus Infections in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Aldape, K; Cheng, K; Ruppin, E; Schäffer, AA; Schiff, E; Sinha, S | 1 |
1 other study(ies) available for erlotinib hydrochloride and Coronavirus Infections
Article | Year |
---|---|
In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression.
Topics: A549 Cells; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Bleomycin; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Drug Design; Drug Evaluation, Preclinical; Erlotinib Hydrochloride; Fluphenazine; HEK293 Cells; Humans; Kidney; Lung; MCF-7 Cells; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; SARS-CoV-2; Systems Biology; Up-Regulation; Vemurafenib | 2020 |